Research study · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2026
Cannabinoid-based interventions for behavioral outcomes in children and adolescents with autism spectrum disorder: A systematic review of safety and effectiveness
Verified on PubMed Systematic review or meta-analysis
A 2026 systematic review in Progress in Neuro-Psychopharmacology and Biological Psychiatry tested cannabinoids. Twelve studies (4 RCTs, 8 non-RCTs) were included in the systematic review. This review clarifies that while one specific whole-plant extract may offer modest social benefits for some children, current evidence does not support routine use of cannabinoids as a standard treatment.
In plain language
Study overview
While observational studies and one RCT suggest modest behavioral and social communication benefits from full-spectrum, high-CBD-to-THC cannabis extracts in pediatric autism spectrum disorder, current robust trial data do not support generalized routine use. Cannabinoids should be reserved as an adjunctive therapeutic option under strict specialist medical supervision, carefully weighing the modest potential benefits against the neurodevelopmental and cognitive risks of pediatric THC exposure.
Findings
Twelve studies (4 RCTs, 8 non-RCTs) were included in the systematic review. One RCT evaluating a whole-plant 20:1 CBD:THC extract demonstrated significant improvements in global clinical impression (CGI-I) and social responsiveness (SRS-2). RCTs investigating isolated CBD (up to 20 mg/kg/day) or specific cannabinoid extracts found no significant differences compared to placebo for primary outcome measures like ATEC, RBS-R, or sleep scores. Observational and cohort studies reported high rates of caregiver-perceived improvement (32% to 90%) and reductions in concomitant psychotropic medications.
The deeper readScientific analysis
Background: Autism spectrum disorder (ASD) lacks effective options for core symptoms. Cannabinoids, especially cannabidiol (CBD) and combined CBD:Δ9-tetrahydrocannabinol (THC) formulations, are of interest, but clinical evidence is heterogeneous. Purpose: To evaluate the effectiveness and safety of cannabinoid-based interventions for behavioral outcomes in children and adolescents with ASD. Methods: Six databases (Scopus, Web of Science, Embase, Cochrane Library, PubMed, PsycINFO) were searched from February 2024 to June 2025. Risk of bias was assessed using RoB 2 (randomized controlled trials [RCTs]) and the Newcastle-Ottawa Scale (non-RCTs); certainty was evaluated with GRADE. Results: Twelve studies (4 RCTs, 8 non-RCTs) were included; six ongoing trials were identified. Most interventions used full-spectrum extracts with high CBD:THC ratios (often 20:1), with titration up to ~10 mg/kg/day; doses varied across studies. Responder rates for global improvement vs placebo (49% vs 21%) and greater improvement in social communication. No between-group differences were observed for sleep or overall symptom severity, and repetitive behaviors showed a non-significant trend toward improvement. Non-RCTs studies suggested benefits but had high risk of bias and very low certainty. Adverse events were mostly mild and non-serious (e.g., somnolence, appetite changes, sleep problems, irritability); no treatment-related serious adverse events were reported. Conclusions: Evidence remains limited. A whole-plant 20:1 extract improved global clinical impression and social communication in one RCT, whereas other standardized outcomes were null. Current data support only cautious, adjunctive use under medical supervision. Larger, well-designed RCTs using validated outcomes are needed to clarify efficacy, optimal formulations, and long-term safety. PROSPERO registration: CRD42024508518.
The paper
Citation
Vasconcelos QDJS, de Freitas RF, Freitas MC, de Andrade IP, Brandão CB, Nascimento CE, et al. Cannabinoid-based interventions for behavioral outcomes in children and adolescents with autism spectrum disorder: A systematic review of safety and effectiveness. Progress in Neuro-Psychopharmacology and Biological Psychiatry (2026). PubMed 41974303 · DOI
Limitations the authors noted
High heterogeneity across study designs, formulations, and outcome measures prevented meta-analysis. Small sample sizes and short treatment durations (typically 8-12 weeks) in RCTs limit statistical power. High placebo responses, particularly in caregiver-reported subjective outcome measures. Frequent reliance on unblinded caregiver-reported rating scales and lack of systematic polypharmacy assessment.
In practice
Why this matters
This review clarifies that while one specific whole-plant extract may offer modest social benefits for some children, current evidence does not support routine use of cannabinoids as a standard treatment for autism spectrum disorder due to inconsistent results and the need for careful specialist supervision.
Browse related research
Condition: Autism Spectrum Disroder Condition: THC Topic: Autism Topic: Cannabinoids Topic: CBD
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on September 19, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.